REMARKS

By this Office Action, the Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

Group I. Claims 1-15, drawn to a method for treating a glycolipid storage-related disorder comprising administering a therapeutically effective amount of an inhibitor of glycolipid synthesis in combination with an agent capable of increasing the rate of glycolipid degradation, classified in class 514.

Group II. Claims 16-24, drawn to a method for treating a glycolipid storage-related disorder comprising administering a therapeutically effective amount of an inhibitor of glycolipid synthesis in combination with bone marrow transplantation, classified in class 424, subclass 93.1.

Group III. Claims 25-38, drawn to a pharmaceutical composition comprising an inhibitor of glycolipid synthesis and an agent capable of increasing the rate of glycolipid degradation, classified in class 514.

Responsive to the Requirement for restriction, Applicants elect to prosecute the invention of Group I, without traverse, Claims 1-15, drawn to a method for treating a glycolipid storage-related disorder comprising administering a therapeutically effective amount of an inhibitor of glycolipid synthesis in combination with an agent capable of increasing the rate of glycolipid degradation, classified in class 514.

No fees are believed to be necessitated by the foregoing Response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

The Examiner has indicated that Applicants are required to elect a single disclosed species of glycolipid synthesis inhibitor, a single disclosed species of agent capable of increasing the rate of glycolipid degradation, and a single disclosed species of glycolipid storage-related disorder for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Accordingly, Applicants elect N-butyldeoxynojirimycin (NB-DNJ) as the species of inhibitor of glycolipid synthesis as it relates on claim 1-3, 9, and 15; glucocerebrosidase as the species of agent capable of increasing the rate of glycolipid

degradation as it relates to claims 1, 10-14, and 15; and Gaucher disease as the species of glycolipid storage-related disorder as it relates to claims 1-15.

In view of the above, withdrawal of the Requirement for the Restriction is requested, and an early action on the merits of the Claims is courteously solicited.

Respectfully submitted,

Sarah J. Fashena

Sarah J. Fashena, Ph.D.
Agent for Applicant(s)
Registration No. 57,600

KLAUBER & JACKSON LLC
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800

Date: January 30, 2006